Biontech has now confirmed the sales forecast for its Covid-19 vaccine of 13 to 17 billion euros this year. According to the company, it expects to publish the first clinical trial data on the safety, tolerability and efficacy of a vaccine adapted to the omicron variant in April, which should support potential applications for approval.
study
About 2,150 adults are participating in the study. The current Covid-19 vaccine and an omicron-based vaccine are being investigated in test people who have already been vaccinated and those who have not been vaccinated before. According to Biontech, the study has been expanded to include several combined approaches. Other vaccine candidates must also be tested.